3/29/2024 0 Comments Rapt therapeutics stockLets take a closer look to see what the different types of shareholders can tell us about RAPT Therapeutics. SOUTH SAN FRANCISCO, Calif., J(GLOBE NEWSWIRE) - RAPT Therapeutics, Inc. In the chart below, we can see that institutional investors have bought into the company. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics has a market capitalization of US1.1b, so we would expect some institutional investors to have noticed the stock. and changed its name to RAPT Therapeutics, Inc. The company was formerly known as FLX Bio, Inc. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. Since coming public at 12. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. Rapt Therapeutics revenue from 2018 to 2021. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |